PRINCETON, N.J. and SAN FRANCISCO , April 14, 2022 /PRNewswire/ — Nektar Therapeutics  (NASDAQ: NKTR) and Bristol Myers Squibb  (NYSE: BMY) today announced that based on results from pre-planned analyses of two late-stage clinical studies of bempegaldesleukin (BEMPEG) in combination with Opdivo

Original Source


Notice: ob_end_flush(): failed to send buffer of zlib output compression (0) in /home/biznews/public_html/wp-includes/functions.php on line 5219